Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439928 · ClinicalTrials.gov registry record · NA
Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 163
- Enrollment target
NCT05439928: Completed NA study, sponsored by Columbia University.
NCT05439928 is a NA study that has completed, run by Columbia University. The registered enrollment target is 163 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439928, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 163 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the use of continuous glucose monitoring (CGM) device DEXCOM G6 in non-critically patients treated for diabetic emergency such as diabetic ketoacidosis (DKA). Patients who have DKA require hourly monitoring of glucose (sugar) level which traditionally requires admission to the intensive care unit (ICU) for hourly fingerstick monitoring. With the use of CGM device, in this research study hourly fingerstick monitoring is replaced by continuous glucose monitor (CGM) which provides glucose levels continuously in real time for nurses and provider. The investigators are testing to see if in the future patients can be treated in the stepdown unit (an intermediate care level between the intensive care unit and the general medical unit) if they do not require higher level of care besides hourly glucose monitoring. Continuous glucose monitoring (CGM) device DEXCOM G6 currently FDA Approved for patients with diabetes and is widely used for glucose monitoring in patients with diabetes in the outpatient setting. The investigators want to study the use of the DEXCOM G6 CGM in the inpatient setting to monitoring glucose levels remotely in the treatment of diabetic emergencies such as diabetic ketoacidosis and compare their care to those receiving hourly fingerstick glucose monitoring in the ICU.
Primary Outcome
Time to resolution of metabolic acidosis measured in hours. Resolution defined as anion gap (AG) \<17 mEq/L and bicarbonate \>19 mEq/L.
Interventions
- DEVICE DEXCOM G6 CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the finished NCT05439928 record still lists
NCT05439928 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which DEXCOM G6 CGM is the first listed.
NCT05439928 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05439928 about?
NCT05439928 is a clinical study titled "Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)". The purpose of this research study is to investigate the use of continuous glucose monitoring (CGM) device DEXCOM G6 in non-critically patients treated for diabetic emergency such as diabetic ketoacidosis (DKA). Patients who have DKA require hourly monitoring of glucose (sugar) level which tradition...
What is the current status of trial NCT05439928?
This trial is currently completed. It is a NA study. The enrollment target is 163 participants. The study started on 2022-06-07. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05439928?
The interventions under investigation include: DEXCOM G6 CGM (DEVICE).
Who is sponsoring clinical trial NCT05439928?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05439928's enrollment target sits among peer trials
163 627th of 2000 higher than 1,374 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI